ANDA 91048, held by Sagent Pharms Inc. Cefepime Hydrochloride.
As of Nov 16, 2026, ANDA 91048 (Cefepime Hydrochloride), held by Sagent Pharms Inc, was first approved by FDA on Jan 4, 2017, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 4, 2017 | Original application | Approved | None posted |
| Cefepime HydrochlorideEQ 1GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Rx |
| Cefepime HydrochlorideEQ 2GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Rx |
| May 21, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 15, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 4, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters